NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq:INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, provided a clinical update from the ongoing Phase 1 trial of INB-100. This program is an allogeneic, or donor-derived, gamma-delta T cell therapeutic candidate in development for patients with high-risk leukemias undergoing haploidentical hematopoietic stem cell transplant (HSCT). William Ho, Chief Executive Officer of IN8bio, will be discussing these results at the 3rd Annual Gamma-Delta T Therapies Summit, being held July 26-28, in Boston.
Read more at globenewswire.comIN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Computer%20board%20micro%20chip%20green%20by%20blickpixel%20via%20Pixabay.jpg){kind=tracking}
